The triad for diagnosing BPDCN and for differentiating it from other things that may be presenting are positive biomarkers CD123, CD4, and CD56; all three must be positive for histopathologic confirmation of BPDCN.
Just as important are markers that come up negative, eg CD3, CD20, MPO, CD34, and lysozyme. While they may be positive in other cancers such as AML, angiosarcomas and melanomas, they are always negative in BPDCN.
Learn more about the immunophenotypic features of BPDCN.
Medscape © 2021 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Emmanuel C. Besa. Fast Five Quiz: Blastic Plasmacytoid Dendritic Cell Neoplasm Presentation and Diagnosis - Medscape - Feb 23, 2021.